RT Journal Article
SR Electronic
T1 Relationship Between Leukotriene Receptor Antagonists on Cancer Development in Patients With Bronchial Asthma: A Retrospective Analysis
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3717
OP 3724
DO 10.21873/anticanres.15861
VO 42
IS 7
A1 MAEDA-MINAMI, AYAKO
A1 HOSOKAWA, MAIKO
A1 ISHIKURA, YUMI
A1 ONODA, ATSUTO
A1 KAWANO, YOHEI
A1 NEGISHI, KENICHI
A1 SHIMADA, SHUJI
A1 IHARA, TOMOMI
A1 SUGAMATA, MASAO
A1 TAKEDA, KEN
A1 MANO, YASUNARI
YR 2022
UL http://ar.iiarjournals.org/content/42/7/3717.abstract
AB Background/Aim: An association between leukotriene receptor antagonists (LTRA) and cancer has been previously reported, but the relationship between LTRA use and cancer prevention remains controversial. This study aimed to clarify the cancer-preventive effect of LTRA in Japanese patients with bronchial asthma. Patients and Methods: We obtained information from a large populationbased medical information database to analyze data on patients who were newly diagnosed with bronchial asthma between 2006 and 2015. Eligible participants were patients who were prescribed an LTRA for at least 30 days (LTRA users) and those who were not using LTRA (LTRA non-users) during the objective period. LTRA users and LTRA non-users were matched 1:1 using propensity scores. Results: The 1:1 propensity score matching of LTRA users and LTRA nonusers facilitated the inclusion of 3,744 participants each, in these two subgroups. The results of the Cox proportional hazards model after adjustment for covariates showed no significant difference in the cancer risk between LTRA users and non-users [adjusted hazard ratio (HR)=0.83, 95% confidence interval (CI)=0.59-1.16]. The subgroup analysis showed no significant difference in the cancer risk between the LTRA low-cumulative dose group and LTRA non-users, or between the LTRA medium-cumulative dose group and LTRA non-users. In contrast, the LTRA high-cumulative dose group had a significantly lower risk of developing cancer compared with LTRA non-users (adjusted HR=0.57, 95% CI=0.33-0.98). Conclusion: LTRA use may prevent cancer in patients with bronchial asthma.